Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Key Benefits of an SMSF

Olivia Long
April 2, 2020

The Bell Direct SMSF Service

Olivia Long
April 2, 2020

Morning Bell 2 April

Jessica Amir
April 2, 2020

Market Update 1 April

Jessica Amir
April 1, 2020

March Market Overview

Jessica Amir
March 31, 2020

Morning Bell 25 March

Jessica Amir
March 25, 2020

Weekly Wrap 20 March

Bell Direct
March 20, 2020

Market Update 20 March

Jessica Amir
March 20, 2020

Market Update 19 March

Jessica Amir
March 19, 2020

Morning Bell 18 March

Jessica Amir
March 18, 2020

Morning Bell 17 March

Jessica Amir
March 17, 2020